Month Six News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Month Six. Real-time updates on events, politics, business and more.

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1 - Alnylam Pharmaceuticals (NASDAQ:ALNY) - Press Release

October 7, 2022

- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patie

United States United Kingdom Jorge Capapey Kim Hollander Hyperoxaluria Foundation Global Rare Disease Lead At Alnylam Pharmaceuticals

Source: wiredprnews.com

Forget '2000 Mules' nonsense. Here are six things the Arizona Legislature should do in June

June 1, 2022

The Arizona Legislature is an embarrassment. Its members should spend less time obsessing about 2000 Mules and more time acting like actual leaders.

United States Sandy Hook El Paso Maricopa County Robb Elementary School Sutherland Springs

Source: azcentral.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Month Six News Today

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO&#xAE; (lumasiran) in Advanced Primary Hyperoxaluria Type 1 - Alnylam Pharmaceuticals (NASDAQ:ALNY) - Press Release

Forget '2000 Mules' nonsense. Here are six things the Arizona Legislature should do in June

Explore More Categories

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1 - Alnylam Pharmaceuticals (NASDAQ:ALNY) - Press Release